Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

5 treatments under study, led by Selinexor

Research Leaders

5 sponsors active, led by USWM CT, LLC

Related Conditions

Often studied with 13 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

4Total
Phase 1 (1)
Phase 1/2 (2)
Phase 2 (1)

Trial Status

Recruiting3
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT05642455Phase 1/2Recruiting

SPEARHEAD-3 Pediatric Study

NCT06735820Phase 1/2RecruitingPrimary

Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST

NCT06849986Phase 2Recruiting

IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)

NCT04811196Phase 1Completed

A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients

Showing all 4 trials

Research Network

Common Treatments

  • Selinexor1
  • Afamitresgene Autoleucel1
  • Apg1151
  • Selumetinib1
  • Tislelizumabliposomal Doxorubicinifosfamide1

Active Sponsors

  • USWM CT, LLC1
  • Fudan University1
  • Children's National Research Institute1
  • University Health Network, Toronto1
  • AeRang Kim1

Top Investigators

Related Conditions

  • Leiomyosarcoma2
  • Osteosarcoma1
  • Fibrosarcoma1
  • Pleomorphic Liposarcoma1
  • Soft Tissue Sarcomas1

Activity Timeline